Table 2.

Pre-clinical studies on combined treatment of HDACi with platinum-based chemotherapeutics

HDACi	Cancer target	Results	Refs
SAHA w/cisplatin	oral squamous cell carcinoma	cisplatin and SAHA increase cytotoxicity and sensitize OSCC cells to apoptosis	[92]
SAHA w/cisplatin	oral squamous cell carcinoma	increases endoplasmic reticulum stress-mediated apoptosis	[93]
SAHA w/cisplatin	oral squamous cell carcinoma cells	Chemosensitization and apoptotic enhancement	[94,95]
SAHA Carboplatin (with Paclitaxel)	advanced solid malignancies (head and neck)	increase anticancer activity (now in clinical trial for advanced solid malignancies	[91]
SAHA w/cisplatin	human glioblastoma (D54), breast cancer (MCF-7)	increases cytotoxicity of cisplatin	[82]
SAHA w/cisplatin	Cervical cancer (HeLa cells)	has synergistic effect on the HeLa cell viability	[88]
VPA w/cisplatin and pemetrexed	mesothelioma (cell cultures & tumor xenografts)	increases antitumor efficacy; being evaluated in phase II trial for refractory/recurrent malignant pleural mesothelioma	[96]
VPA w/cisplatin	head and neck squamous cell carcinoma (HNSCC)	enhances the anticancer activity of cisplatin in HNSCC cell lines	[97]
VPA w/cisplatin	human ovarian cancer (SK- OV-3, OVCAR-3, and TOV- 21G)	synergistic cytotoxicity with cisplatin; enhances cisplatin- mediated cytotoxicity in resistant cancer cells	[98]
VPA w/cisplatin	M14 melanoma cells	sensitizes M14 cells to chemotherapy treatment	[99]
FK-228 MS-275, TSA	human ovarian & colon cancer cell lines	enhances cytotoxic effects reduced dose of chemo agent	[100]
PCI-24781	soft tissue sarcoma	enhances cytotoxic effects	[19]
TSA	human glioblastoma (D54) breast cancer (MCF-7)	increases cytotoxicity of cisplatin	[82]
TSA	Human Bladder Cancer Cell Line	resensitizes cisplatin- resistant human bladder cancer cells	[101]
MS-275	human oral squamous carcinoma cells	enhanceds cytotoxicity, chemosensitization, and apoptosis	[95]